|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang M, Yang C, Dong W, Zhao Y, Chen N
and Gao C: Expression patterns and prognostic role of m6A RNA
methylation regulators in Non-small Cell Lung Cancer. Cell Mol Biol
(Noisy-le-grand). 70:67–72. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zheng X, Qiu L, Huang Y, Cheng R, Huang S,
Xu K, Cai W, Deng Y, Wang W, Zhong X, et al: Exploring the
molecular and Immune-landscape of lung cancer associated with
cystic airspaces. Mol Immunol. 168:75–88. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hamza MS and Mousa SA: Cancer-Associated
Thrombosis: Risk factors, molecular mechanisms, future management.
Clin Appl Thromb Hemost. 26:10760296209542822020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Korte W: Changes of the coagulation and
fibrinolysis system in malignancy: Their possible impact on future
diagnostic and therapeutic procedures. Clin Chem Lab Med.
38:679–692. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mulder FI, Horváth-Puhó E, van Es N, van
Laarhoven HWM, Pedersen L, Moik F, Ay C, Büller HR and Sørensen HT:
Venous thromboembolism in cancer patients: A Population-based
cohort study. Blood. 137:1959–1969. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tatsumi K: The pathogenesis of
Cancer-associated thrombosis. Int J Hematol. 119:495–504. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tieken C and Versteeg HH: Anticoagulants
versus cancer. Thromb Res. 140 (Suppl 1):S148–S153. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kawai K and Watanabe T: Colorectal cancer
and hypercoagulability. Surg Today. 44:797–803. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Saidak Z, Soudet S, Lottin M, Salle V,
Sevestre MA, Clatot F and Galmiche A: A pan-cancer analysis of the
human tumor coagulome and its link to the tumor immune
microenvironment. Cancer Immunol Immunother. 70:923–933. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Song B, Chi H, Peng G, Song Y, Cui Z, Zhu
Y, Chen G, Wu J, Liu W, Dong C, et al: Characterization of
coagulation-related gene signature to predict prognosis and tumor
immune microenvironment in skin cutaneous melanoma. Front Oncol.
12:9752552022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang B, Zou D, Wang N, Wang H, Zhang T,
Gao L, Ma C, Zheng P, Gu B, Li X, et al: Construction and
validation of a novel Coagulation-related 7-gene prognostic
signature for gastric cancer. Front Genet. 13:9576552022.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang WX, Gao HW, Cui JB, Zhang AA, Wang
FF, Xie JQ, Lu MH and You CG: Development and validation of a
coagulation-related genes prognostic model for hepatocellular
carcinoma. BMC Bioinformatics. 24:892023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Palta S, Saroa R and Palta A: Overview of
the coagulation system. Indian J Anaesth. 58:515–523. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Langer F and Bokemeyer C: Crosstalk
between cancer and haemostasis. Implications for cancer biology and
cancer-associated thrombosis with focus on tissue factor.
Hamostaseologie. 32:95–104. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lima LG and Monteiro RQ: Activation of
blood coagulation in cancer: Implications for tumour progression.
Biosci Rep. 33:2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Y and Wei S: Advances on mechanisms of
coagulation with non-small cell lung cancer. Zhongguo Fei Ai Za
Zhi. 16:676–680. 2013.(In Chinese). PubMed/NCBI
|
|
20
|
Du H and Chen J: Occurrence of venous
thromboembolism in patients with lung cancer and its anticoagulant
therapy. Zhongguo Fei Ai Za Zhi. 21:784–789. 2018.(In Chinese).
PubMed/NCBI
|
|
21
|
Neacşu F, Vârban A, Simion G, Şurghie R,
Pătraşcu OM, Sajin M, Dumitru M and Vrînceanu D: Lung cancer
mimickers-a case series of seven patients and review of the
literature. Rom J Morphol Embryol. 62:697–704. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Herrera I, Cisneros J, Maldonado M,
Ramírez R, Ortiz-Quintero B, Anso E, Chandel NS, Selman M and Pardo
A: Matrix metalloproteinase (MMP)-1 induces lung alveolar
epithelial cell migration and proliferation, protects from
apoptosis, and represses mitochondrial oxygen consumption. J Biol
Chem. 288:25964–25975. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jiang S, Liu H, Zhang J, Zhang F, Fan J
and Liu Y: MMP1 regulated by NEAT1/miR-361-5p axis facilitates the
proliferation and migration of cutaneous squamous cell carcinoma
via the activation of Wnt pathway. Cancer Biol Ther. 22:381–391.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu H, Lan T, Li H, Xu L, Chen X, Liao H,
Chen X, Du J, Cai Y, Wang J, et al: Circular RNA circDLC1 inhibits
MMP1-mediated liver cancer progression via interaction with HuR.
Theranostics. 11:1396–1411. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang K, Zheng J, Yu J, Wu Y, Guo J, Xu Z
and Sun X: Knockdown of MMP-1 inhibits the progression of
colorectal cancer by suppressing the PI3K/Akt/c-myc signaling
pathway and EMT. Oncol Rep. 43:1103–1112. 2020.PubMed/NCBI
|
|
26
|
Guo J, Jin G, Hu Y, Zhao Z, Nan F, Hu X,
Hu Y and Han Q: Wogonin restrains the malignant progression of lung
cancer through modulating MMP1 and PI3K/AKT signaling pathway.
Protein Pept Lett. 30:25–34. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rempe RG, Hartz AMS and Bauer B: Matrix
metalloproteinases in the brain and Blood-brain barrier: Versatile
breakers and makers. J Cereb Blood Flow Metab. 36:1481–1507. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen Y, Zhou Y, Chen J, Yang J, Yuan Y and
Wu W: Exosomal lncRNA SNHG12 promotes angiogenesis and breast
cancer progression. Breast Cancer. 31:607–620. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Faraj Shaglouf LH, Ranjpour M, Wajid S and
Jain SK: Elevated expression of cellular SYNE1, MMP10, and GTPase1
and their regulatory role in hepatocellular carcinoma progression.
Protoplasma. 257:157–167. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
He L, Kang Q, Chan KI, Zhang Y, Zhong Z
and Tan W: The immunomodulatory role of matrix metalloproteinases
in colitis-associated cancer. Front Immunol. 13:10939902022.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bi Y, Cao K, Wang Y, Yang W, Ma N, Lei X
and Chen Y: Radiosensitivity in non-small-cell lung cancer by MMP10
through the DNA damage repair pathway. J Oncol. 2023:56368522023.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lin CL, Hung TW, Ying TH, Lin CJ, Hsieh YH
and Chen CM: Praeruptorin B mitigates the metastatic ability of
human renal carcinoma cells through targeting CTSC and CTSV
Expression. Int J Mol Sci. 21:29192020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu J, Zhang W, Wang Z, Wang Y, Li T, Wang
Y, Ding J and Ning B: Cathepsin V is correlated with the prognosis
and tumor microenvironment in liver cancer. Mol Carcinog.
63:400–416. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sereesongsaeng N, Burrows JF, Scott CJ,
Brix K and Burden RE: Cathepsin V regulates cell cycle progression
and histone stability in the nucleus of breast cancer cells. Front
Pharmacol. 14:12714352023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhu L, Zeng Q, Wang J, Deng F and Jin S:
Cathepsin V drives lung cancer progression by shaping the
immunosuppressive environment and adhesion molecules cleavage.
Aging (Albany NY). 15:13961–13979. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu L, Li J, Fan C, Wen M, Li C, Sun W and
Wang W: Construction of a new Immune-related competing endogenous
rna network with prognostic value in lung adenocarcinoma. Mol
Biotechnol. 66:300–310. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xu S, Tuo QZ, Meng J, Wu XL, Li CL and Lei
P: Thrombin induces ferroptosis in triple-negative breast cancer
through the cPLA2α/ACSL4 signaling pathway. Transl Oncol.
39:1018172024. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu J, Li L, Zhang H, Zhao Y, Zhang H, Wu S
and Xu B: A risk model developed based on tumor microenvironment
predicts overall survival and associates with tumor immunity of
patients with lung adenocarcinoma. Oncogene. 40:4413–4424. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hwang C, Lee SJ, Lee JH, Kim KH, Suh DS,
Kwon BS and Choi KU: Stromal tumor-infiltrating lymphocytes
evaluated on H&E-stained slides are an independent prognostic
factor in epithelial ovarian cancer and ovarian serous carcinoma.
Oncol Lett. 17:4557–4565. 2019.PubMed/NCBI
|
|
40
|
Paijens ST, Vledder A, de Bruyn M and
Nijman HW: Tumor-infiltrating lymphocytes in the immunotherapy era.
Cell Mol Immunol. 18:842–859. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shaban M, Khurram SA, Fraz MM, Alsubaie N,
Masood I, Mushtaq S, Hassan M, Loya A and Rajpoot NM: A Novel
digital score for abundance of tumour infiltrating lymphocytes
predicts disease free survival in oral squamous cell carcinoma. Sci
Rep. 9:133412019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Choi A, Jung YW and Choi H: The extrinsic
factors important to the homeostasis of Allergen-specific memory
CD4 T cells. Front Immunol. 13:10808552022. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kawabe T and Sher A: Memory-phenotype CD4+
T cells: A naturally arising T lymphocyte population possessing
innate immune function. Int Immunol. 34:189–196. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Krueger PD, Osum KC and Jenkins MK: CD4+
memory T-cell formation during type 1 immune responses. Cold Spring
Harb Perspect Biol. 13:a0381412021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Okła K, Farber DL and Zou W:
Tissue-resident memory T cells in tumor immunity and immunotherapy.
J Exp Med. 218:e202016052021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Park SL, Gebhardt T and Mackay LK:
Tissue-resident memory T cells in cancer immunosurveillance. Trends
Immunol. 40:735–747. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang H, Zhu Z, Modrak S and Little A:
Tissue-resident memory CD4+ T cells play a dominant role
in the initiation of antitumor immunity. J Immunol. 208:2837–2846.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Parrish-Novak J, Dillon SR, Nelson A,
Hammond A, Sprecher C, Gross JA, Johnston J, Madden K, Xu W, West
J, et al: Interleukin 21 and its receptor are involved in NK cell
expansion and regulation of lymphocyte function. Nature. 408:57–63.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Xu C, Sui S, Shang Y, Yu Z, Han J, Zhang
G, Ntim M, Hu M, Gong P, Chen H and Zhang X: The landscape of
immune cell infiltration and its clinical implications of
pancreatic ductal adenocarcinoma. J Adv Res. 24:139–148. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chang J, Wu H, Wu J, Liu M, Zhang W, Hu Y,
Zhang X, Xu J, Li L, Yu P and Zhu J: Constructing a novel
mitochondrial-related gene signature for evaluating the tumor
immune microenvironment and predicting survival in stomach
adenocarcinoma. J Transl Med. 21:1912023. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sun X, Li J, Gao X, Huang Y, Pang Z, Lv L,
Li H, Liu H and Zhu L: Disulfidptosis-related lncRNA prognosis
model to predict survival therapeutic response prediction in lung
adenocarcinoma. Oncol Lett. 28:3422024. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Mogi A and Kuwano H: TP53 mutations in
nonsmall cell lung cancer. J Biomed Biotechnol.
2011:5839292011.PubMed/NCBI
|
|
53
|
Perez-Rivas LG, Simon J, Albani A, Tang S,
Roeber S, Assié G, Deutschbein T, Fassnacht M, Gadelha MR, Hermus
AR, et al: TP53 mutations in functional corticotroph tumors are
linked to invasion and worse clinical outcome. Acta Neuropathol
Commun. 10:1392022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Chen H, Deng J, Hou TW and Shan YQ:
Villosol reverses 5-FU resistance in colorectal cancer by
inhibiting the CDKN2A gene regulated TP53-PI3K/Akt signaling axis.
J Ethnopharmacol. 325:1179072024. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhong Y, Wang J, Lv W, Xu J, Mei S and
Shan A: LncRNA TTN-AS1 drives invasion and migration of lung
adenocarcinoma cells via modulation of miR-4677-3p/ZEB1 axis. J
Cell Biochem. 120:17131–17141. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Mack KN, Samuels ZV, Carter LM, Viray TD,
Mandleywala K, Brooks CL, Hollingsworth MA, Radhakrishnan P and
Lewis JS: Interrogating the theranostic capacity of a
MUC16-Targeted antibody for ovarian cancer. J Nucl Med. 65:580–585.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Aguilar EN, Sagar S, Murray BR, Rajesh C,
Lei EK, Michaud SA, Goodlett DR, Caffrey TC, Grandgenett PM,
Swanson B, et al: Structural basis for multivalent MUC16
recognition and robust Anti-pancreatic cancer activity of humanized
antibody AR9.6. Mol Cancer Ther. 23:836–853. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Liu T, Wu L, Liu J, Chen H, Zhu B, Qiao D,
Zhu Y, Liu T, Chen Q and Hu A: Comprehensive characterization of
MUC16 mutations in lung adenocarcinoma for immunotherapies and
prognosis: An observational study. Medicine (Baltimore).
102:e354812023. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Liu C, Zheng S, Wang Z, Wang S, Wang X,
Yang L, Xu H, Cao Z, Feng X, Xue Q, et al: KRAS-G12D mutation
drives immune suppression and the primary resistance of
anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer. Cancer
Commun (Lond). 42:828–847. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wen Y, Tang F, Tu C, Hornicek F, Duan Z
and Min L: Immune checkpoints in osteosarcoma: Recent advances and
therapeutic potential. Cancer Lett. 547:2158872022. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Jardim DL, Goodman A, de Melo Gagliato D
and Kurzrock R: The challenges of tumor mutational burden as an
immunotherapy biomarker. Cancer Cell. 39:154–173. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Liu L, Bai X, Wang J, Tang XR, Wu DH, Du
SS, Du XJ, Zhang YW, Zhu HB, Fang Y, et al: Combination of TMB and
CNA stratifies prognostic and predictive responses to immunotherapy
across metastatic cancer. Clin Cancer Res. 25:7413–7423. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Samstein RM, Lee CH, Shoushtari AN,
Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ,
Omuro A, et al: Tumor mutational load predicts survival after
immunotherapy across multiple cancer types. Nat Genet. 51:202–206.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Ricciuti B, Wang X, Alessi JV, Rizvi H,
Mahadevan NR, Li YY, Polio A, Lindsay J, Umeton R, Sinha R, et al:
Association of high tumor mutation burden in Non-small cell lung
cancers with increased immune infiltration and improved clinical
outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA
Oncol. 8:1160–1168. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Cao D, Xu H, Xu X, Guo T and Ge W: High
tumor mutation burden predicts better efficacy of immunotherapy: A
pooled analysis of 103078 cancer patients. Oncoimmunology.
8:e16292582019. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Ding D, Wang L, Zhang Y, Shi K and Shen Y:
Machine learning developed a programmed cell death signature for
predicting prognosis and immunotherapy benefits in lung
adenocarcinoma. Transl Oncol. 38:1017842023. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Müller-Tidow C, Bug G, Lübbert M, Krämer
A, Krauter J, Valent P, Nachbaur D, Berdel WE, Ottmann OG, Fritsch
H, et al: A randomized, open-label, phase I/II trial to investigate
the maximum tolerated dose of the Polo-like kinase inhibitor BI
2536 in elderly patients with refractory/relapsed acute myeloid
leukaemia. Br J Haematol. 163:214–222. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Liu L, Zhang B, Wu X, Cheng G, Han X, Xin
X, Qin C, Yang L, Huo M and Yin L: Bioresponsive nanocomplex
integrating cancer-associated fibroblast deactivation and
immunogenic chemotherapy for rebuilding immune-excluded tumors.
Nanomedicine. 58:1027432024. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zhang X, Yu T, Gao G, Xu J, Lin R, Pan Z,
Liu J and Feng W: Cell division cycle 42 effector protein 4
inhibits prostate cancer progression by suppressing ERK signaling
pathway. Biomol Biomed. 24:840–847. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Mi K, Zeng L, Chen Y, Ning J, Zhang S,
Zhao P and Yang S: DHX38 enhances proliferation, metastasis, and
EMT progression in NSCLC through the G3BP1-mediated MAPK pathway.
Cell Signal. 113:1109622024. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Jeon Y, Park S, Lee SH, Kim TH, Kim SW,
Ahn MJ, Jung HA and Chung JH: Combination of dabrafenib and
trametinib in patients with metastatic BRAFV600E-Mutated thyroid
cancer. Cancer Res Treat. 56:1270–1276. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Zeng B, Liao X, Liu L, Zhang C, Ruan H and
Yang B: Thyroid hormone mediates cardioprotection against
postinfarction remodeling and dysfunction through the
IGF-1/PI3K/AKT signaling pathway. Life Sci. 267:1189772021.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Shi X, Han X and Cao Y, Li C and Cao Y:
ZCCHC14 regulates proliferation and invasion of non-small cell lung
cancer through the MAPK-P38 signalling pathway. J Cell Mol Med.
25:1406–1414. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Ling Y, Li J and Zhou L: Smoking-related
epigenetic modifications are associated with the prognosis and
chemotherapeutics of patients with bladder cancer. Int J
Immunopathol Pharmacol. 37:39463202311667742023. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Prahallad A, Weiss A, Voshol H, Kerr G,
Sprouffske K, Yuan T, Ruddy D, Meistertzheim M, Kazic-Legueux M,
Kottarathil T, et al: CRISPR screening identifies mechanisms of
resistance to KRASG12C and SHP2 inhibitor combinations in Non-Small
cell lung cancer. Cancer Res. 83:4130–4141. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Phyu SM, Tseng CC and Smith TAD:
CDP-choline accumulation in breast and colorectal cancer cells
treated with a GSK-3-targeting inhibitor. Magma. 32:227–235. 2019.
View Article : Google Scholar : PubMed/NCBI
|
